BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10172083)

  • 21. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
    Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
    Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
    Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
    Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW; Bernstein SH
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation.
    Nemunaitis J; Buckner CD; Appelbaum FR; Higano CS; Mori M; Bianco J; Epstein C; Lipani J; Hansen J; Storb R
    Blood; 1991 May; 77(9):2065-71. PubMed ID: 1902125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease.
    Gulati SC; Bennett CL
    Ann Intern Med; 1992 Feb; 116(3):177-82. PubMed ID: 1728202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy.
    Nemunaitis J; Singer JW; Buckner CD; Mori T; Laponi J; Hill R; Storb R; Sullivan KM; Hansen JA; Appelbaum FR
    Bone Marrow Transplant; 1991 Jan; 7(1):49-52. PubMed ID: 2043878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation.
    Pene R; Appelbaum FR; Fisher L; Lilleby K; Nemunaitis J; Storb R; Buckner CD
    Bone Marrow Transplant; 1993 Mar; 11(3):219-22. PubMed ID: 8467286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
    Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors.
    Nemunaitis J; Anasetti C; Storb R; Bianco JA; Buckner CD; Onetto N; Martin P; Sanders J; Sullivan K; Mori M
    Blood; 1992 May; 79(10):2572-7. PubMed ID: 1586709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
    Goa KL; Bryson HM
    Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous and allogeneic bone marrow transplantation.
    Nemunaitis J; Singer JW
    Cancer Invest; 1993; 11(2):224-8. PubMed ID: 8462023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
    Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
    Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Granulocyte-macrophage colony-stimulating factor. Treatment of patients with highly malignant lymphomas and acute lymphoblastic leukemias after autologous bone marrow transplantation].
    Jessen P; Nielsen B; Jensen IM; Ellegaard J; Hokland P
    Ugeskr Laeger; 1992 Dec; 154(52):3754-7. PubMed ID: 1471304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
    Sallerfors B; Olofsson T; Lenhoff S
    Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Chao NJ; Schriber JR; Long GD; Negrin RS; Catolico M; Brown BW; Miller LL; Blume KG
    Blood; 1994 May; 83(10):2823-8. PubMed ID: 7514046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.
    Calderwood S; Doyle JJ; Hitzler JK; Saunders EF; Freedman MH
    Bone Marrow Transplant; 1996 Jul; 18(1):87-91. PubMed ID: 8832000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.